Fabry Disease Treatment Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Drugs (Agalsidase Beta, Migalastat, others), By Treatment (Enzyme Replacement Therapy (ERT), Chaperone Treatment, Substrate Reduction Therapy (SRT), others), By Route of Administration (Oral, Parenteral, others), By Distribution Channel (Hospital pharmacies, Retail pharmacies, On
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationFabry Disease Treatment Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Drugs (Agalsidase Beta, Migalastat, others), By Treatment (Enzyme Replacement Therapy (ERT), Chaperone Treatment, Substrate Reduction Therapy (SRT), others), By Route of Administration (Oral, Parenteral, others), By Distribution Channel (Hospital pharmacies, Retail pharmacies, On
| Forecast Period | 2024-2028 |
| Market Size (2022) | USD1862.50 million |
| CAGR (2024-2028) | 6.30% |
| Fastest Growing Segment | Online Pharmacies |
| Largest Market | North America |
Market Overview
Global Fabry Disease Treatment Market has valued at USD 1862.50 million in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 6.30% through 2028. Fabry disease, also known as Anderson-Fabry disease, is a rare and inherited genetic disorder that belongs to a group of conditions known as lysosomal storage disorders. This disease is caused by mutations in the GLA gene, which encodes an enzyme called alpha-galactosidase A (alpha-Gal A). The deficiency of this enzyme results in the accumulation of a specific type of fatty substance, known as globotriaosylceramide (Gb3 or GL-3), within cells throughout the body. This buildup of Gb3 primarily affects the cells of blood vessels, kidneys, heart, and nervous system, leading to a wide range of symptoms and complications. Symptoms of Fabry disease often appear in childhood or adolescence, although the age of symptom onset and their severity can vary widely among affected individuals. One of the hallmark symptoms of Fabry disease is neuropathic pain, which can be severe and chronic. This pain typically affects the extremities, such as the hands and feet, and is often described as burning or tingling.
Growing awareness among healthcare professionals, patients, and caregivers about Fabry disease has led to improved diagnosis rates. Increased awareness is a significant driver for the market, as early diagnosis is critical for initiating treatment. Advances in diagnostic tools and genetic testing have made it easier to identify Fabry disease, even in its early stages. Improved diagnostic capabilities have led to more cases being diagnosed and treated. Global healthcare expenditure has been increasing, allowing for greater investment in rare disease treatments like Fabry disease. Increased healthcare budgets have supported research and development efforts and improved patient access to treatments. Pharmaceutical companies have been investing in research and development to develop novel therapies for Fabry disease. This includes gene therapy, chaperone therapy, and other innovative treatment options, expanding the market. Advances in biotechnology and drug delivery methods have improved the safety and efficacy of Fabry disease treatments, making them more attractive to patients and healthcare providers.
Key Market Drivers
Advancements in Diagnosis
Genetic testing has become a cornerstone in the diagnosis of Fabry disease. Advances in genetic sequencing technology have made it more accessible and cost-effective to identify specific mutations in the GLA gene, which is responsible for the disease. Genetic testing can confirm the presence of Fabry disease and provide information about the specific genetic mutations involved. In some regions, newborn screening programs have been implemented to identify Fabry disease in infants shortly after birth. This early detection allows for prompt intervention and treatment, potentially preventing or delaying the onset of symptoms and organ damage. Researchers have been investigating biomarkers associated with Fabry disease. Biomarkers are measurable substances in the body that can indicate the presence of a disease or its progression. Biomarker research can aid in early diagnosis and monitoring the effectiveness of treatment. Clinical diagnostic criteria for Fabry disease have been refined and standardized. Healthcare professionals now have clearer guidelines and criteria to assist in diagnosing disease based on clinical symptoms and genetic testing results.
Advanced imaging techniques, such as magnetic resonance imaging (MRI) and echocardiography, can help visualize organ damage caused by Fabry disease. These non-invasive methods allow for the assessment of heart, kidney, and other organ involvement. Enzyme activity assays, which measure the activity of alpha-galactosidase A, the deficient enzyme in Fabry disease, have become more precise and widely found at. These assays can confirm the enzyme deficiency in individuals suspected of having the disease. Telemedicine and telehealth technologies have expanded access to Fabry disease specialists, allowing patients to receive consultations and diagnostic evaluations remotely. This is especially important for individuals in underserved or remote areas. Collaboration among healthcare professionals, researchers, and patient advocacy groups on a global scale has facilitated the sharing of diagnostic knowledge and best practices, leading to more accurate and consistent diagnosis. Healthcare providers are increasingly educated about Fabry disease, leading to better recognition and diagnosis of the condition. Continuing medical education programs and resources have contributed to this improvement. Fabry disease patients and their families have become more informed and proactive in seeking a diagnosis. Online resources and patient advocacy groups have empowered individuals to advocate for their healthcare needs. This factor will help in the development of the Global Fabry Disease Treatment Market.
Rising Pharmaceutical Innovation
Pharmaceutical companies invest in research and development to create novel and more effective treatments for Fabry disease. These innovations can lead to therapies that are better at managing the disease, reducing symptoms, and improving the quality of life for patients. Pharmaceutical innovation leads to a broader range of treatment options for Fabry disease. This diversification of therapies allows healthcare providers and patients to choose the most appropriate treatment based on individual needs, preferences, and disease characteristics. Advancements in pharmaceutical research enable the development of targeted therapies. These treatments are designed to address the specific molecular and genetic mechanisms underlying Fabry disease. Targeted therapies can be more effective and have fewer side effects than traditional treatments. Pharmaceutical innovation supports the concept of personalized medicine, where treatments are tailored to an individual's genetic profile and disease characteristics. This approach can lead to more precise and effective treatments, optimizing patient outcomes. Innovations in drug delivery technology can enhance the convenience and effectiveness of Fabry disease treatments. For example, advancements in enzyme replacement therapy (ERT) delivery methods can make it easier for patients to receive treatment. Pharmaceutical research can lead to the development of therapies that require less frequent administration. This can improve patient adherence to treatment regimens and reduce the burden of frequent hospital visits.
Many pharmaceutical companies pursue orphan drug designations for Fabry disease treatments. These designations provide incentives and regulatory support for the development of treatments for rare diseases, increasing investment in this area. Pharmaceutical companies conduct clinical trials to test the safety and efficacy of new Fabry disease treatments. These trials provide valuable data on the benefits and risks of innovative therapies and help bring them to market. Competition among pharmaceutical companies can drive innovation by encouraging the development of new and improved Fabry disease treatments. This competition can lead to better treatment options and potentially lower costs for patients. As pharmaceutical companies expand their presence in global markets, access to Fabry disease treatments improves for patients in different regions, increasing demand for these therapies. Patient advocacy groups and organizations often collaborate with pharmaceutical companies in research and development efforts. This collaboration can accelerate the development and availability of innovative treatments. This factor will pace up the demand of the Global Fabry Disease Treatment Market.
Increasing Disease Awareness
Disease awareness campaigns educate healthcare providers and the public about Fabry disease, its symptoms, and risk factors. This knowledge can lead to earlier diagnosis, enabling patients to access treatment before the disease progresses to more severe stages. Improved awareness can help reduce delays in diagnosis. Fabry disease is often underdiagnosed or misdiagnosed because its symptoms can mimic other conditions. Increased awareness among healthcare professionals can lead to more accurate and timely diagnoses. When people become more aware of Fabry disease, they may seek medical advice and testing if they exhibit symptoms or have a family history of the disease. This can result in more individuals being tested for Fabry disease, potentially leading to earlier identification and treatment. Awareness campaigns are often driven by patient advocacy groups and organizations. These groups work to raise awareness about Fabry disease, support affected individuals, and advocate for better access to treatment and resources. Disease awareness initiatives often include educational programs for healthcare providers. These programs help physicians recognize the signs and symptoms of Fabry disease and consider it as a potential diagnosis when evaluating patients.
Disease awareness efforts provide patients and their families with accurate information about Fabry disease, found at treatments, and support services. Informed patients are more likely to seek appropriate care and treatment options. Raising awareness can reduce the stigma associated with rare diseases like Fabry disease. This can encourage individuals to discuss their symptoms openly with healthcare providers and seek help without fear of judgment. Increased awareness can lead to greater interest from pharmaceutical companies and researchers in developing new and improved Fabry disease treatments. As the demand for treatments grows, so does the incentive for innovation in the field. Public awareness campaigns can garner support from policymakers and government agencies. This support can lead to increased funding for research, improved healthcare policies, and better access to treatment. Disease awareness is not limited by geographical boundaries. Global collaboration among healthcare organizations, advocacy groups, and researchers can further drive awareness and foster international efforts to combat Fabry disease. This factor will accelerate the demand of the Global Fabry Disease Treatment Market.
Key Market Challenges
Limited Patient Population
The small patient population with Fabry disease results in a limited market size for pharmaceutical companies. This can make it less economically attractive for these companies to invest in research and development of treatments for disease. Developing and gaining regulatory approval for new treatments, including clinical trials and research, is costly. In the case of rare diseases like Fabry disease, the small number of potential patients can make it challenging to recoup these expenses. Due to the small market size, the revenue potential for treatments for Fabry disease may be limited compared to drugs for more common conditions. This can affect the profitability of drug development efforts. Limited patient populations can result in challenges related to patient access to treatments and affordability. Even if effective treatments exist, they may not be accessible to all patients due to cost or availability. The rarity of Fabry disease can lead to delayed diagnosis or misdiagnosis, as healthcare providers may not be familiar with the condition. This can result in patients not receiving appropriate treatment until the disease has progressed. Limited patient populations can also result in a scarcity of clinical data on the disease and its treatment. This can make it challenging for healthcare providers to make informed treatment decisions. Recognizing the challenges posed by rare diseases, some regulatory agencies provide incentives for orphan drug development. These incentives can include extended market exclusivity and reduced regulatory fees.
Supply Chain Vulnerabilities
The primary treatment for Fabry disease involves enzyme replacement therapy, which can be costly. ERT drugs are typically administered intravenously every two weeks, and the cost of these treatments can accumulate significantly over time. Fabry disease is a chronic condition that requires lifelong treatment. The long-term nature of treatment can result in a substantial financial burden on patients and healthcare systems. Access to ERT and other Fabry disease treatments may be limited in some regions. Even when treatments are found at, not all patients may have adequate insurance coverage to offset the costs, leading to disparities in access to care. Patients with Fabry disease often require ongoing medical care, including monitoring for complications in various organs (e.g., heart, kidneys) and managing associated symptoms. These additional healthcare expenses can further contribute to the overall cost of treatment. From a pharmaceutical industry perspective, developing and bringing Fabry disease treatments to market can be expensive due to the need for extensive research, clinical trials, and regulatory approvals. These costs can influence the pricing of therapies. Fabry disease is a rare condition, and the limited patient population can result in higher treatment costs per patient. Pharmaceutical companies may need to recover development costs from a smaller pool of patients, which can lead to higher drug prices. Many Fabry disease treatments receive orphan drug designation, which provides certain incentives to pharmaceutical companies but can also result in higher drug prices.
Key Market Trends
Biomarker Development
Biomarkers can aid in the early diagnosis of Fabry disease, allowing for timely intervention and treatment initiation. Early diagnosis is essential for preventing or delaying the onset of symptoms and organ damage. Biomarkers can be used to monitor disease progression and assess the effectiveness of treatment over time. This enables healthcare providers to tailor treatment plans to individual patients' needs. Certain biomarkers may be associated with the severity of Fabry disease. Identifying these biomarkers can help predict disease outcomes and guide treatment decisions. Biomarkers can help determine how well a patient is responding to treatment. If treatment is effective, biomarkers may show improvements in disease-related indicators. Biomarkers can serve as valuable endpoints in clinical trials of new Fabry disease treatments. They provide objective measures of treatment efficacy and safety. The development of biomarkers supports the concept of personalized medicine, where treatments are tailored to individual patients based on their biomarker profiles. This approach can optimize treatment outcomes. Biomarkers provide insights into the underlying molecular and genetic mechanisms of Fabry disease. This knowledge can inform drug development efforts, leading to more targeted and effective therapies. Biomarkers can be used to stratify Fabry disease patients into different subgroups based on disease characteristics. This stratification can guide treatment decisions and improve patient outcomes. Biomarkers can help reduce diagnostic delays by providing objective evidence of Fabry disease. This is particularly important because Fabry disease is often underdiagnosed or misdiagnosed.
Segmental Insights
Drugs Insights
In 2022, the Global Fabry Disease Treatment Market largest share was held by Agalsidase Beta segment and is predicted to continue expanding over the coming years.
Treatment Insights
In 2022, the Global Fabry Disease Treatment Market largest share was held by Enzyme Replacement Therapy (ERT) segment and is predicted to continue expanding over the coming years.
Route of Administration Insights
In 2022, the Global Fabry Disease Treatment Market largest share was held by Oral segment and is predicted to continue expanding over the coming years.
Distribution Channel Insights
In 2022, the Global Fabry Disease Treatment Market largest share was held by
Regional Insights
The North America region dominates the Global Fabry Disease Treatment Market in 2022.
Recent Developments
- In May 2023, ProtalixBioTherapeutics, Inc., a biopharmaceutical company focused on the developmentand commercialization of recombinant therapeutic proteins expressed through itsproprietary plant cell-based expression system, ProCellEx, and Chiesi GlobalRare Diseases, a business unit of the Chiesi Group established to deliverinnovative therapies and solutions for people affected by rare diseases,announced that the U.S. Food and Drug Administration (FDA) has approvedELFABRIO. A PEGylated enzymereplacement therapy (ERT) is ELFABRIO. Galactosidase-A is a recombinant humanenzyme that is produced in plant cells and has a lengthy half-life.
- In May 2023, The FDA hasapproved isaralgagene civaparvovec, also known as ST-920, a wholly owned genetherapy product candidate for the treatment of Fabry disease, according toSangamo Therapeutics, Inc., a genomic medicine business. A novel therapy that is designed to treat serious or life-threateningillnesses and that has the potential to meet unmet medical needs is given FastTrack classification to facilitate its development and quicken its evaluation.An opportunity for more regular engagement with the FDA is provided tocompanies who receive this classification. These clinical programmes could alsobe qualified to apply for Priority Review and Accelerated Approval provided thenecessary requirements are satisfied. Prior until now, the FDA designatedST-920 as an orphan drug.
Key Market Players
- Sanofi (GenzymeCorporation)
- Takeda PharmaceuticalCompany Limited
- Amicus Therapeutics, Inc
- ISU ABXIS Co Ltd.
- JCR Pharmaceuticals Co.,Ltd.
- Protalix BioTherapeuticsInc.
- Chiesi Farmaceutici S.p.A.
- Freeline TherapeuticsHoldings PLC
- Yuhan Corporation
- M6P Therapeutics
| By Drugs | By Treatment | By Route of Administration | By Distribution Channel | By Region | By Region |
|
|
|
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy